At ImmunityBio, we're driven by a patient-first culture that guides everything we do. Our team of scientists, doctors, and staff work tirelessly to transform living biological technologies into innovative treatments for cancer and infectious diseases. We believe in empowering the body's own immune system - rather than weakening it - by developing therapies that activate both innate and adaptive immune responses to create durable, complete responses.
Our scientific approach centers on a proprietary natural killer cell platform that can be expanded, genetically modified, and cryopreserved. With 27 clinical trials across 13 indications, our lead product ANKTIVA® (N-803) has earned FDA Breakthrough Therapy designation for BCG-unresponsive non-muscle invasive bladder cancer. Founded by Dr. Patrick Soon-Shiong in 2014, we've grown into a clinical-stage biotechnology company with deep expertise in genomics, proteomics, monoclonal antibodies, fusion proteins, vaccines, and autologous and allogeneic cell therapies. Our success is measured not by milestones, but by the quality of life we can offer patients who need these therapies most.
